Copy Link Print Information

8-OH-DPAT hydrobromide

(Synonyms: 8-Hydroxy-DPAT hydrobromide)
9 Cited Publications
Customer Review

Based on 9 publication(s) in Google Scholar

8-OH-DPAT (8-Hydroxy-DPAT) hydrobromide is a potent, brain-penetrant and selective 5-HT1A agonist with a pIC50 of 8.19. 8-OH-DPAT hydrobromide has selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site.

For research use only. We do not sell to patients.

  • Purity: 99.88%
  • CAS No.: 76135-31-4
  • Formula: C16H26BrNO
  • Molecular Weight:328.29
  • Storage:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

  • 8-OH-DPAT hydrobromide Chemical Structure
    8-OH-DPAT hydrobromide Chemical Structure
  • Experimental Validation Results for 8-OH-DPAT hydrobromide
  • Experimental Validation Results for 8-OH-DPAT hydrobromide
  • Experimental Validation Results for 8-OH-DPAT hydrobromide
  • Experimental Validation Results for 8-OH-DPAT hydrobromide
CAS No.: 76135-31-4
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of 8-OH-DPAT hydrobromide:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Chemical Information
  • Solvent & Solubility
  • Purity & Documentation
  • References
  • Help & FAQs
You May Still Need
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) 8-OH-DPAT hydrobromide

More
Customer Validation & Images
In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study

All 5-HT Receptor Isoforms

More
Keywords
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Register
Sign in to MedChemExpress
Register New Account

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • 8-OH-DPAT hydrobromide Chemical Structure
    8-OH-DPAT hydrobromide Chemical Structure
    1/16
  • 1/16

    8-OH-DPAT hydrobromide purchased from MedChemExpress. Usage Cited in: J Ethnopharmacol. 2026 Feb 28:357:120876. [Abstract]

    Customer Validation
     Microinjecting 8-OH-DPAT (4 mM) into the dorsal raphe nucleus (DRN) followed by AITC ME treatment. TST (F (3,28) = 3.435, P = 0.0303, n = 8) and FST (F (3,28) = 14.79, P < 0.0001, n = 8) were performed 2 h later. The results showed that 8-OH-DPAT, a 5-HT₁AR agonist, abolished the antidepressant activity of AITC ME, indicating that the antidepressant effect of AITC ME was associated with the autoreceptor-mediated negative feedback mechanism of 5-HT₁AR in the DRN.

  • 1/16

    8-OH-DPAT hydrobromide purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2025 Oct 9. [Abstract]

    Customer Validation
     Microinjecting 8-OH-DPAT (4  mM) into the dorsal raphe nucleus (DRN), followed by esflurbiprofen treatment (20 mg/kg, intraperitoneally) at 5 min. TST (F (3, 28) = 6.237, P = 0.0022), FST (F (3, 28) = 4.385, P = 0.0119) were performed 2 h post treatment (n = 8). The results showed that 8-OH-DPAT, a selective 5-HT₁A receptor agonist, abolished the rapid antidepressant activity of esflurbiprofen, confirming that esflurbiprofen exerted antidepressant effects by inhibiting the negative feedback mediated by 5-HT₁A autoreceptors.

  • 1/16

    8-OH-DPAT hydrobromide purchased from MedChemExpress. Usage Cited in: Neurochem Int. 2025 Mar:184:105937. [Abstract]

    Customer Validation
     Statistical analysis of the percentage of c-Fos+ TPH2+ cells in the experimental groups of mice (n = 6, with samples from at least three mice per group). The results showed that treatment with SA-4503 (1.0 mg/kg; p.o. ; once daily for 3 days), alone or in combination with 8-OH-DPAT (0.3 mg/kg ; i.g.; once daily for 3 days), activated a greater number of serotonergic neurons in the DRN of mice subjected to CRS. Similarly, the combined treatment significantly enhanced the effect of 8-OH-DPAT alone (P = 0.0022).

  • 1/16

    8-OH-DPAT hydrobromide purchased from MedChemExpress. Usage Cited in: Mol Neurobiol. 2025 Nov 24;63(1):163. [Abstract]

    Customer Validation
     Co-administration of the sigma-1 receptor (S1R) agonist SA-4503 (1 mg/kg, i.p.) and the 5-HT₁A receptor agonist 8-OH-DPAT (0.3 mg/kg, i.p.) produced synergistic anxiolytic- and antidepressant-like effects.

  • 8-OH-DPAT hydrobromide